Billionaire Ray Dalio Trims Place

Johnson & Johnson (NYSE:JNJ) is likely one of the 15 Finest Shares to Purchase In response to Billionaire Ray Dalio.

Johnson & Johnson (NYSE:JNJ) has featured within the 13F portfolio of Bridgewater Associates for greater than a decade and a half. The fund has held a small place within the firm since early 2011, rising this stake to 4.71 million shares at its peak within the second quarter of 2022. Since then, it has trimmed this holding. Filings for the fourth quarter of 2025 present that the fund owned 1.31 million shares within the pharmaceutical, biotechnology, and medical applied sciences company. This stake represents a lower of 23% in comparison with filings for the earlier quarter. The inventory is among the many prime fifteen greatest positions of Dalio, per the 13F portfolio.

READ NEXT: 33 Shares That Ought to Double in 3 Years.

Johnson & Johnson (NYSE:JNJ) is favored by institutional traders as a result of it has a formidable dividend historical past stretching again greater than six many years. The corporate has a historical past of dividend progress that has lasted for sixty-three years, and counting. For the reason that 2023 spinoff of the buyer well being enterprise by Johnson & Johnson, hedge funds view the corporate as a higher-margin, faster-growing firm. By focusing solely on Revolutionary Medication and MedTech, JNJ has accelerated its income progress. In early 2026, the corporate forecast gross sales of $100 billion, exceeding Wall Avenue estimates. Funds are significantly bullish on the blockbuster most cancers drug Darzalex, which surpassed expectations in This autumn 2025, and the brand new remedy Carvykti, which hit $1 billion in annual gross sales for the primary time.

Whereas we acknowledge the potential of JNJ as an funding, we consider sure AI shares supply higher upside potential and carry much less draw back threat. For those who’re in search of an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.

READ NEXT: 33 Shares That Ought to Double in 3 Years and 15 Shares That Will Make You Wealthy in 10 Years

Disclosure: None. Observe Insider Monkey on Google Information